Epharmix Featured in Forbes

December 2, 2019 / Nueterra Capital Marketing

Epharmix | A Nueterra Capital Portfolio Company

In its latest Technology Council article, Forbes cites Epharmix’s EpxCOPD tool as an example of how remote patient monitoring makes it possible for more patients to leave the hospital setting and return home. EpxCOPD provides daily breathing status monitoring for COPD patients and has been able to prevent one hospitalization for every nine patients using the tool. You can read the full article here.